Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
-
Comparative Study Clinical Trial
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
A considerable amount of experimental and clinical data prove the cytoprotective effect of amifostine on normal tissue exposed to different types of antineoplastic treatments. The present study examines its influence on the short-term toxicity of either radiotherapy alone or combined radio-chemotherapy in patients with advanced head and neck cancer. ⋯ The application of amifostine before each radiation treatment seems to result in a distinct reduction of short-term toxicity of radiotherapy or combined radio-chemotherapy in patients with head and neck cancer, allowing for a better adherence to the planned radiation time schedule.
-
Randomized Controlled Trial Comparative Study Clinical Trial
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Experimental and clinical data suggest a reduction of radiation-induced acute toxicity by amifostine. We investigated this issue in a randomized trial comparing radiochemotherapy (RCT) versus radiochemotherapy and amifostine (RCT + A) in patients with head and neck cancer. ⋯ According to our preliminary results amifostine has a radioprotective effect on salivary glands. Mucositis can be reduced during radiochemotherapy. At this point of patient accrual the difference between both groups are statistically not significant. To improve the radioprotective effects of amifostine in clinical practice the application of a higher dose (> 250 mg) seems to be necessary.
-
Ewing's tumors are sensitive to radio- and chemotherapy. Patients with multifocal disease suffer a poor prognosis. Patients presenting primary bone marrow involvement or bone metastases at diagnosis herald a 3-year disease-free survival below 15%. The European Intergroup Cooperative Ewing's Sarcoma Study (EICESS) has established the following indications for high-dose therapy in advanced Ewing's tumors: Patients with primary multifocal bone disease, patients with early (< 2 years after diagnosis) or multifocal relapse. ⋯ High-dose chemotherapy can improve outcome in poor prognostic advanced Ewing's tumors. The disease itself remains the main problem. The expected engraftment problems after intensive radiotherapy in large volumes of bone marrow can be overcome by stem cell reinfusion.
-
This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively. ⋯ Postoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival.
-
Regularly the Institute of Scientific Information publishes the impact factor (IF) that plays an increasing role when the scientific quality of scientific performances of journals, single publications, scientists, and research groups have to be evaluated in order to support them. ⋯ Evaluation of scientific performances by IF is to be restricted to journals and large research groups. Fairness demands comparisons to homogeneous journals with respect to confounders such as language. Principally, no journal should be excluded to obtain an IF if it fulfills the minimum criteria of an internationally communicating science. For this purpose they have to provide a title, key words, and an abstract in English, a peer review system etc. Often journals are the centre of science cultures that are able to generate research of highest levels. The users can contribute to increase the IF of "their" journal and to care for the valid application of this indicator.